NasdaqGM:IOVABiotechs
Iovance Biotherapeutics Q4 Loss Narrows To US$0.18 EPS And Tests Bearish Narratives
Iovance Biotherapeutics (IOVA) closed out FY 2025 with fourth quarter revenue of US$86.8 million and a basic EPS loss of US$0.18, alongside a quarterly net loss of US$71.9 million. The company has seen quarterly revenue move from US$73.7 million in Q4 2024 to US$86.8 million in Q4 2025, while basic EPS shifted from a loss of US$0.26 to a loss of US$0.18 over the same period, setting up a results season where investors are weighing growing sales against ongoing losses. With trailing twelve...